The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Revenue reached $17.8 billion ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Total revenue of $17.8 billion in the quarter ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management. Notably, Pfizer's R&D ...

Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products topped expectations and its broad cost-cutting efforts took hold.

Revenue from COVID vaccine Comirnaty brought in sales of $3.38 billion, while antiviral treatment Paxlovid was $727 million for the quarter. Pfizer makes the Comirnaty vaccine with German partner ...